The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...

icc world cup live A new potential anti-cancer target - PRL2 Trikafta, a triple combination therapy for CF in patients with specific gene mutations, reaches endpoint in Phase III clinical trial Nature ...

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

The issue with CFTR modulators is that they don’t work on every CF case. However, the company developed its competitive edge ...

Jurrien Timmer, Director of Global Macro at Fidelity Management & Research Company, recently shared his outlook for the stock ...

The task ahead of Vertex now is to migrate patients already on Trikafta to the new drug. That is supported by data from the ...

Throughout Gunnar Esiason's journey with cystic fibrosis, the sport of hockey has always been huge part of his family. See ...

The FDA's nod is based on late-stage data, which show that treatment with VRTX's Alyftrek enhances patient benefit compared ...

Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...

Alyftrek is approved as a new treatment for cystic fibrosis, while the FDA expanded the label for Trikafta to include additional genetic mutations.

The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion ...

As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...